Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention
- PMID: 16521129
- PMCID: PMC7168515
- DOI: 10.1002/med.20055
Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention
Abstract
A novel human coronavirus (CoV) has been identified as the etiological agent that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. The spike (S) protein of this virus is a type I surface glycoprotein that mediates binding of the virus to the host receptor and the subsequent fusion between the viral and host membranes. Because of its critical role in viral entry, the S protein is an important target for the development of anti-SARS CoV therapeutics and prophylactics. This article reviews the structure and function of the SARS CoV S protein in the context of its role in virus entry. Topics that are discussed include: the interaction between the S1 domain of the SARS spike protein and the cellular receptor, angiotensin converting enzyme 2 (ACE2), and the structural features of the ectodomain of ACE2; the antigenic determinants presented by the S protein and the nature of neutralizing monoclonal antibodies that are elicited in vivo; the structure of the 4,3-hydrophobic heptad repeats HR1 and HR2 of the S2 domain and their interaction to form a six-helical bundle during the final stages of fusion. Opportunities for the design and development of anti-SARS agents based on the inhibition of receptor binding, the therapeutic uses of S-directed monoclonal antibodies and inhibitors of HR1-HR2 complex formation are presented.
Copyright 2006 Wiley Periodicals, Inc.
Similar articles
-
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.J Virol. 2020 Jul 1;94(14):e00635-20. doi: 10.1128/JVI.00635-20. Print 2020 Jul 1. J Virol. 2020. PMID: 32376627 Free PMC article.
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Nat Rev Microbiol. 2009. PMID: 19198616 Free PMC article. Review.
-
Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.Antivir Ther. 2007;12(4 Pt B):639-50. Antivir Ther. 2007. PMID: 17944271 Review.
-
Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus.Cell Mol Life Sci. 2004 Nov;61(21):2738-43. doi: 10.1007/s00018-004-4242-5. Cell Mol Life Sci. 2004. PMID: 15549175 Free PMC article. Review.
-
Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.J Virol. 2010 Dec;84(24):12658-64. doi: 10.1128/JVI.01542-10. Epub 2010 Oct 6. J Virol. 2010. PMID: 20926566 Free PMC article.
Cited by
-
Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.Antiviral Res. 2009 Jan;81(1):82-7. doi: 10.1016/j.antiviral.2008.10.001. Epub 2008 Nov 5. Antiviral Res. 2009. PMID: 18983873 Free PMC article.
-
Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches.Biochem Biophys Rep. 2024 Jun 12;39:101745. doi: 10.1016/j.bbrep.2024.101745. eCollection 2024 Sep. Biochem Biophys Rep. 2024. PMID: 38974021 Free PMC article.
-
Therapeutic strategies for critically ill patients with COVID-19.Ann Intensive Care. 2020 Apr 20;10(1):45. doi: 10.1186/s13613-020-00661-z. Ann Intensive Care. 2020. PMID: 32307593 Free PMC article. Review.
-
COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.Front Pharmacol. 2020 Oct 16;11:563478. doi: 10.3389/fphar.2020.563478. eCollection 2020. Front Pharmacol. 2020. PMID: 33178016 Free PMC article. Review.
-
Impaired angiogenesis in aminopeptidase N-null mice.Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4588-93. doi: 10.1073/pnas.0611653104. Epub 2007 Mar 7. Proc Natl Acad Sci U S A. 2007. PMID: 17360568 Free PMC article.
References
-
- World Health Organization . http://www.who.int/topics/sars/en
-
- Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen M‐H, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TCT, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen‐Rasmussen M, Fouchier R, Günther S, Osterhaus ADME, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394–1399. - PubMed
-
- Marra MA, Jones SJM, Astell CR, Holt RA, Brooks‐Wilson A, Butterfield YSN, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Girn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smailus DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czub M, Drebot M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL. The genome sequence of the SARS‐associated coronavirus. Science 2003; 300: 1399–1404. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous